British Startup Raises Millions to Become the Illumina for Epigenetics

14/03/2016 - 3 minutes

Cambridge Epigenetix (UK) wants to unlock the power of the Epigenome and become what Illumina is for NGS. And now, it has gotten the €18.9M and a new CEO needed to achieve this.

cambridge_epigenix_oxsbCambrige Epigenetix is a Biotech developing epigenetic tools, and was initially founded by Cambridge Enterprise (an incubator of the University of Cambridge) and Syncona Partners – one of the top 15 VCs in Europe.

This Biotech went on to raise about €4.3M ($5.5M) in late 2014, adding well-known New Science Ventures (which also participated in Forbion-led investment in NASH) to its investor roll.

Now, Epigenetix has raised around €18.9M ($21M) in a series B round, and from very interesting investors. These are GV (formerly Google Ventures) and Sequoia Capital – one of the most prominent VCs in Silicon Valley.

This is another case of conventional Tech investors going for Biotech companies. But why did they choose this particular Biotech?

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member